Founders Capital Management LLC decreased its position in Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,164 shares of the company’s stock after selling 348 shares during the period. Johnson & Johnson makes up about 1.2% of Founders Capital Management LLC’s portfolio, making the stock its 23rd biggest holding. Founders Capital Management LLC’s holdings in Johnson & Johnson were worth $4,622,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Lincoln Capital Corp raised its stake in shares of Johnson & Johnson by 15.9% during the 3rd quarter. Lincoln Capital Corp now owns 1,332 shares of the company’s stock valued at $218,000 after buying an additional 183 shares during the last quarter. Ieq Capital LLC raised its stake in shares of Johnson & Johnson by 5.1% during the 3rd quarter. Ieq Capital LLC now owns 128,012 shares of the company’s stock valued at $20,912,000 after buying an additional 6,154 shares during the last quarter. RFG Advisory LLC raised its stake in shares of Johnson & Johnson by 2.7% during the 3rd quarter. RFG Advisory LLC now owns 22,434 shares of the company’s stock valued at $3,900,000 after buying an additional 594 shares during the last quarter. Willis Investment Counsel raised its stake in shares of Johnson & Johnson by 0.4% during the 4th quarter. Willis Investment Counsel now owns 328,884 shares of the company’s stock valued at $58,097,000 after buying an additional 1,358 shares during the last quarter. Finally, FDx Advisors Inc. raised its stake in shares of Johnson & Johnson by 0.3% during the 3rd quarter. FDx Advisors Inc. now owns 50,421 shares of the company’s stock valued at $8,237,000 after buying an additional 153 shares during the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.
Wall Street Analyst Weigh In
JNJ has been the subject of several recent analyst reports. Citigroup lifted their price target on Johnson & Johnson from $198.00 to $205.00 and gave the company a “buy” rating in a research note on Monday, December 12th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, February 1st. Guggenheim initiated coverage on Johnson & Johnson in a research note on Tuesday, February 28th. They issued a “neutral” rating and a $161.00 price target for the company. UBS Group initiated coverage on Johnson & Johnson in a research note on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price target for the company. Finally, Piper Sandler cut their price target on Johnson & Johnson from $55.00 to $52.00 in a research note on Monday, February 6th. Eight investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $173.67.
Johnson & Johnson Trading Up 1.0 %
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping the consensus estimate of $2.22 by $0.13. The business had revenue of $23.71 billion for the quarter, compared to analysts’ expectations of $23.90 billion. Johnson & Johnson had a return on equity of 35.76% and a net margin of 18.90%. The business’s revenue for the quarter was down 4.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.13 EPS. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.5 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The business also recently announced a quarterly dividend, which was paid on Tuesday, March 7th. Stockholders of record on Tuesday, February 21st were issued a dividend of $1.13 per share. This represents a $4.52 annualized dividend and a dividend yield of 2.92%. The ex-dividend date was Friday, February 17th. Johnson & Johnson’s dividend payout ratio is currently 67.06%.
Insider Transactions at Johnson & Johnson
In other news, insider James D. Swanson sold 1,062 shares of the business’s stock in a transaction that occurred on Monday, March 6th. The stock was sold at an average price of $154.66, for a total transaction of $164,248.92. Following the transaction, the insider now directly owns 9,215 shares in the company, valued at approximately $1,425,191.90. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 0.35% of the company’s stock.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.
Featured Stories
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- MarketBeat Week in Review – 3/27 – 3/31
- What is a Gold IRA, and is it a Viable Investment?
- Is Braze Inc Ready To Rocket Higher?
- Mullen Automotive Makes Deliveries; Short-Squeeze Possible
- Can Frontline Maintain This Momentum?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Get Rating).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
